#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Oncology in Images
Giant Metastatic Testicular Tumor


Authors: P. Szturz;  O. Bednařík;  D. Brančíková;  Z. Mechl;  J. Mayer
Authors place of work: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, School of Medicine
Published in the journal: Klin Onkol 2013; 26(4): 298
Category: Různé

Obdrženo: 25. 6. 2013

A 53‑year- old male was referred to a surgery emergency department for a suspected incarcerated inguinal hernia. Developing slowly over a period of one year, the physical examination showed a tough, right- inguinal mass (30 by 15 by 15 cm) with mild tenderness to palpation and erythematous overlying skin (Fig. 1). Furthermore, right lower extremity edema and hemiplegia on the opposite side were evident. With a general cachectic appearance (BMI = 18.9) and lethargy, the patient’s other medical history was remarkable only for a smoking addiction. Laboratory investigations noted elevations of lactate dehydrogenase (46.47 ukat/ L, normal range: 2.25– 3.75 U/ L), uric acid (610 umol/ L, normal range: 202– 417 umol/ L), alkaline phosphatase (6.83 ukat/ L, normal range: 0.67– 2.15 ukat/ L) and C- reactive protein (52.6 mg/ L, normal range: 0– 5 mg/ L). Abdominal ultrasonography revealed a tumorous infiltration of the right scrotum and pelvic area with parailiac lymphadenopathy. The pathological finding of a bio­psied specimen was consistent with classical seminoma. Brain magnetic resonance imaging identified possible metastatic spread in the right basal ganglia, explaining the neurological symptomatology. The patient was not eligible for surgery and due to his poor performance status (Karnofsky score 30), he was indicated for chemotherapy in reduced dosage, which led to improved nutrition, amelioration of hemiplegia, normalization of bio­chemistry results and significant tumor regression (Fig. 2). Despite extensive initial tumor burden, the patient did not develop tumor lysis syndrome.

Fig. 1 Initial disease extent (January 2012).
Fig. 1 Initial disease extent (January 2012).

Fig. 2 Effect of systemic chemotherapy (August 2012).
Fig. 2 Effect of systemic chemotherapy (August 2012).

Germ cell testis tumors exceeding 400 g in weight are rare. Even in their advanced stages, cure rates exceeding 80% have been achieved using cisplatin‑ and carboplatin‑based regimens. However, due to the side effects of cisplatin (nefro‑, neuro‑ and oto- toxicities), carboplatin (mye­losuppression) and bleomycin (pulmonary toxicity), their indications should be cautiously tailored to the patients’ general state and comorbidities. Poor performance status and initial disease extent were identified as relevant adverse pretreatment factors in patients receiving chemotherapy containing cisplatin and bleomycin. Herein, we demonstrated encouraging therapy outcome in a patient with seriously impaired health due to a giant inoperable disseminated classical seminoma.

This work was supported by project MUNI/ /A/0723/2012 and by MH CZ – DRO (FNBr, 65269705).

Petr Szturz, M.D., Ph.D.

Department of Internal Medicine, Hematology and Oncology

University Hospital Brno

Jihlavska 20, 625 00 Brno

e-mail: petr.szturz@fnbrno.cz

Submitted: 25. 6. 2013


Štítky
Dětská onkologie Chirurgie všeobecná Onkologie

Článek vyšel v časopise

Klinická onkologie

Číslo 4

2013 Číslo 4
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Svět praktické medicíny 3/2024 (znalostní test z časopisu)
nový kurz

Kardiologické projevy hypereozinofilií
Autoři: prof. MUDr. Petr Němec, Ph.D.

Střevní příprava před kolonoskopií
Autoři: MUDr. Klára Kmochová, Ph.D.

Aktuální možnosti diagnostiky a léčby litiáz
Autoři: MUDr. Tomáš Ürge, PhD.

Závislosti moderní doby – digitální závislosti a hypnotika
Autoři: MUDr. Vladimír Kmoch

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#